Sponsors › Hoffmann-La Roche

Hoffmann-La Roche

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Hoffmann-La Roche, drawn from ClinicalTrials.gov and Drugs@FDA.

Hoffmann-La Roche is a commercial sponsor with 8 trials in the incretin class on file here, across 5 molecules. The programme is split between 4 early-stage trials and 4 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2027-11-12.

Molecules: exenatide · liraglutide · petrelintide · semaglutide · tirzepatide
Trials on file: 8
Active trials: 6
Results scheduled: 4
Approved FDA submissions: 0

Results due

Est. completion	Drug	Trial	Phase	Participants
2027-11-12	petrelintide	A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight NCT07589686	P2	486
2028-02-05	semaglutide	A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes NCT07112872	P2	330
2028-10-20	petrelintide	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes NCT07843485	P3	600
2028-12-21	petrelintide	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity NCT07843498	P3	3,900

Trials on file

All 8 incretin trials recorded for this sponsor, active first.

Drug	Trial	Status	Phase	Participants
petrelintide	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity NCT07843498	Recruiting	P3	3,900
petrelintide	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease NCT07843472	Recruiting	P3	2,500
petrelintide	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes NCT07843485	Recruiting	P3	600
petrelintide	A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight NCT07589686	Not yet recruiting	P2	486
semaglutide	A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes NCT07112872	Active, not recruiting	P2	330
tirzepatide	A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity NCT06965413	Active, not recruiting	P2	285
exenatide	A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. NCT00717457	Completed	P3	1,189
liraglutide	Study of RO6807952 in Patients With Diabetes Mellitus Type 2 NCT01516476	Terminated	P2	2